Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Two Brain Regions Shrink Before Hippocampus in Early Alzheimer’s Disease, Study Finds

November 18, 2026 Health Desk Health

Research published in NeuroImage: Reports reveals two specific brain regions, the entorhinal cortex and the amygdala, exhibiting atrophy and volume loss years before the hippocampus—the primary memory center—shows signs of Alzheimer’s disease.

Key Clinical Takeaways:

  • Early changes in the entorhinal cortex and amygdala can precede clinical symptoms by up to a decade.
  • Researchers identified these regions as promising new biomarkers for risk stratification and early detection.
  • The findings suggest a potential paradigm shift toward treating neurodegenerative changes before memory impairment occurs.

The typical diagnostic pathway for Alzheimer’s disease, which is the leading cause of dementia worldwide, often relies on observing functional decline in the hippocampus. This focus, however, means that when symptoms appear, the disease has often progressed significantly.

A study led by researchers at Johns Hopkins University suggests a critical window of opportunity exists earlier in the disease’s pathogenesis. This work, presented at Neuroscience 2026 and published in NeuroImage: Reports, details the identification of the entorhinal cortex and the amygdala as regions experiencing significant structural changes in the pre-clinical phases of Alzheimer’s disease.

Identifying Structural Changes in Early-Stage Alzheimer’s

The research utilized a comprehensive analysis of hundreds of magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Two separate sources supplied the information examined: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study.

This longitudinal approach allowed the team to track structural changes across individuals who were symptom-free, those presenting with cognitive impairment, and those who succumbed to the disease. The findings demonstrate that these early structural shifts are not merely incidental but are spatially localized, correlating with known pathological markers of the disease.

The specific regions examined—the entorhinal cortex and the amygdala—are critical to cognitive function. The entorhinal cortex is responsible for the retrieval of established memories. The amygdala, conversely, is linked to the processing of emotional memory. The researchers observed that atrophy in these two regions occurred at a greater rate relative to the hippocampus during the early phases of the disease, according to the team.

Michael Miller, a biomedical engineer and senior author on the study, stated, “We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms.”

This observation underscores a fundamental gap in current clinical practice, where intervention often occurs only after irreversible neurodegeneration has progressed significantly. The research team’s goal is to shift the clinical focus from managing late-stage symptoms to preventing or delaying the disease’s progression during these pre-symptomatic years.

The Promise of Pre-Symptomatic Risk Assessment

The identification of these novel biomarkers offers a potential pathway for dramatically altering the risk profile of individuals who may be prone to Alzheimer’s. The researchers demonstrated that the gray matter atrophy occurring in the entorhinal cortex and amygdala coincided with changes in tau protein, a well-known hallmark of Alzheimer’s pathology, as measured by PET imaging and digital pathology. This connection between structural atrophy and biochemical markers strengthens the findings.

Marilyn Albert, co-author and director of the Johns Hopkins Alzheimer’s Disease Research Center, emphasized the strategic importance of this early detection capability. She noted, “Our goal is to be able to treat individuals before the symptoms of Alzheimer’s disease develop so that they may be delayed or even stopped.” This represents a major advancement in the field of preventative neurology, moving beyond late-stage symptomatic management towards primary, proactive intervention.

Patients in their 30s and 40s who have relatives affected by Alzheimer’s or who have other worries may be candidates for physicians to begin imaging those newly identified brain areas. This allows for proactive monitoring and intervention during the early phases of neurodegeneration, when therapeutic windows are theoretically widest. Professionals concerned with preventative neurology and advanced cognitive screening should consult with specialists who utilize state-of-the-art diagnostic imaging techniques.

The study’s findings establish the entorhinal cortex and the amygdala as promising new biomarkers for early risk stratification.

Meaghan Morris, a neuropathologist who contributed to the research, said that “This could really play into better risk stratification for identifying who is going to have cognitive decline in the near future—and treating people earlier and earlier to hopefully slow the course of the disease.” This ability to identify vulnerable individuals before clinical decline is a critical step toward personalized medicine.

While the initial identification of these regions is a major discovery, the researchers acknowledge that substantial work is needed to translate these clinical observations into a definitive diagnostic tool. The next phase of the research demands a deeper understanding of the underlying biological mechanisms. The team plans to investigate the molecular neighborhoods associated with the observed tau protein changes, aiming to correlate the observed atrophy with specific cellular events.

Michael Miller elaborated on the future direction of the work: “Once we know more about the molecular neighborhoods, we can develop therapies.”

This indicates that the next steps involve moving beyond identifying the problem—the early atrophy—to understanding the precise biological drivers of the pathology, which is necessary for the development of effective molecular interventions. The eventual goal is to delay, or potentially halt, the insidious progression of the disease.

Implications for Clinical Practice and Research

The integration of MRI and PET data to localize gray matter atrophy with tau pathology provides a reliable mechanism for advancing the standard of care.

The use of two large, independent cohorts strengthens the reliability of the findings, suggesting that this pattern of atrophy is not an isolated phenomenon but a systemic feature of early Alzheimer’s pathogenesis. This research contributes to the broader global effort to understand the complex interplay between structural brain changes and neurodegenerative biomarkers.

The availability of advanced brain scanning technology is anticipated to accelerate the adoption of these findings. As technology becomes more affordable and accessible, the ability to screen for these specific biomarkers could revolutionize how physicians approach cognitive health. Patients and their families seeking information on proactive health measures or early diagnostic assessments should consult with reputable specialists in neurological conditions and cognitive health.

The research team’s detailed analysis of the positional associations of MRI atrophy across the Alzheimer’s Disease spectrum, published in NeuroImage: Reports, continues to advance the understanding of the disease’s trajectory. Michael Miller et al. published their findings in the journal, DOI: 10.1016/j.ynirp.2026.100392, detailing the rostral associations of atrophy in the amygdala and entorhinal cortex across the full spectrum of Alzheimer’s disease.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • FDA Approves Bepirovirsen: The First Antisense Oligonucleotide Therapy for Chronic Hepatitis B
  • Pixel 11 Pro HiLight Now Works With WhatsApp Messages

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service